Will Blood Clot Issues Make Johnson & Johnson’s COVID Vaccine a Loser?

1 min read

Concerns about an extremely rare blood-clotting issue have sidelined Johnson & Johnson‘s (NYSE: JNJ) COVID-19 vaccine for now. An advisory committee is scheduled to meet again on Friday, April 23, to review the data for reported cases of blood clots. In this Motley Fool Live video recorded on April 14, 2021, Motley Fool contributors Keith Speights and Brian Orelli whether or not this possible side effect could make Johnson & Johnson’s vaccine a loser over the longer term.

Continue reading

Leave a Reply

Your email address will not be published.

Previous Story

Forget Coinbase: These Are 3 of the Best Stocks You Can Buy Right Now

Next Story

Better Buy: Lululemon vs. Peloton

Latest from Blog